The FDA has issued warning letters blasting any number of Indian API and drugmakers for not carefully testing drugs or sometimes fabricating test results of batches of their products that they shipped to the U.S. Now the agency has sent a warning letter to an Indian contractor some companies rely on for product testing and analysis, noting repeat violations of GMP standards.
GlaxoSmithKline is still dealing with the aftermath of its China bribery scandal. As the dust settles, the company is rehiring a former senior Chinese employee once suspected of blowing the whistle on GSK in the country.
GlaxoSmithKline's malaria jab got the green light from the EMA on Friday and the British pharma is making plans for a gradual rollout of the vaccine.
According to reports posted on the EudraGMDP site, regulators from Italy recommended bans on specific products made by Jinan Jinda Pharmaceutical in Shandong Province in China and Wuxi Jida Pharmaceutical in Jiangsu City, China, as well as Parabolic Drugs in Haryana, India.
GE Healthcare is betting that a more than $1 billion investment over 5 years to train more than 2 million global healthcare providers will pay off. In developed economies, it's looking to ingratiate itself by offering options for improving efficiency as the demand for value-based healthcare looms, while in emerging economies it hopes to establish itself firmly as more people are able to receive basic healthcare.
Despite strong contributions from fingerstick-free blood glucose monitor Freestyle Libre and mitral valve repair device MitraClip--medical devices remained the worst performing business for Abbott Laboratories last quarter as sales climbed 3.1% on an operational basis to $1.3 billion.
Indian drugmaker Biocon is on the road to taking its in-house CRO public, and the company's founder said she's considering making the company an entirely independent operation.
India has fought long and hard for more price caps on essential medicines in the country, with a parliamentary committee in April lobbying for expanded government price control despite pushback from Big Pharma. Now, as part of its latest crusade, the country is extending price caps for two more antibiotics and setting new prices for branded meds.
Companies in India's diamond-cutting district in Surat, Gujurat, are applying their knowledge of lasers to create something else: stents.
The Indian government is forging ahead with its plan to put price controls on medical devices, the most controversial element of an array of reforms designed to bolster the use and manufacture of devices in India.